TriangleNCT00698685 · OUTCOME
Actuarial Probability of Donor Hematopoietic Engraftment (Defined as at Least 50% Donor DNA in Bone Marrow at Day 100).
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- participants
- Interval / dispersion
- Not reported
- Time frame
- Day 100 after transplant.
What was measured
The number of participants with donor hematopoietic engraftment at day 100 is reported in the data table, and the actuarial probability is calculated using the Kaplan-Meier product-limit estimate statistic, as reported in the statistical analysis section below.
Analysis population: All participants who completed treatment and underwent allogeneic transplant.
Groups in this outcome
Preparative Regimen of Pentostatin and Alemtuzumab
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic \[related or unrelated\] Hematopoietic SCT. Pentostatin: 4 mg/m2/24 hour IV continuously over 72 hours on days -8 to -6. Alemtuzumab: 20 mg per dose IV over 8 hours on days -5 to -1. Patients then received infusion of related or unrelated donor peripheral blood progenitor cells on day 0. Patients also receive cyclosporine IV continuously beginning on day -2, continuing (IV or orally) until day 100, followed by a taper.
| Group | Source count |
|---|---|
| Preparative Regimen of Pentostatin and Alemtuzumab | 12 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Preparative Regimen of Pentostatin and Alemtuzumab | 4 | Not reported | Not reported | Not reported | Not reported |
Source statistical analyses
- ci Pct Value
- 95
- estimate Comment
- Actuarial probability of engraftment at day +100 is calculated according to the product-limit estimate method.
- group Ids
- OG000
- non Inferiority Type
- SUPERIORITY_OR_OTHER
- param Type
- actuarial probability of engraftment
- param Value
- 70
Complete source fields
- analyses
- ci Pct Value
- 95
- estimate Comment
- Actuarial probability of engraftment at day +100 is calculated according to the product-limit estimate method.
- group Ids
- OG000
- non Inferiority Type
- SUPERIORITY_OR_OTHER
- param Type
- actuarial probability of engraftment
- param Value
- 70
- classes
- categories
- measurements
- group Id
- OG000
- value
- 4
- denoms
- counts
- group Id
- OG000
- value
- 12
- units
- Participants
- description
- The number of participants with donor hematopoietic engraftment at day 100 is reported in the data table, and the actuarial probability is calculated using the Kaplan-Meier product-limit estimate statistic, as reported in the statistical analysis section below.
- groups
- description
- Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic \[related or unrelated\] Hematopoietic SCT. Pentostatin: 4 mg/m2/24 hour IV continuously over 72 hours on days -8 to -6. Alemtuzumab: 20 mg per dose IV over 8 hours on days -5 to -1. Patients then received infusion of related or unrelated donor peripheral blood progenitor cells on day 0. Patients also receive cyclosporine IV continuously beginning on day -2, continuing (IV or orally) until day 100, followed by a taper.
- id
- OG000
- title
- Preparative Regimen of Pentostatin and Alemtuzumab
- param Type
- NUMBER
- population Description
- All participants who completed treatment and underwent allogeneic transplant.
- reporting Status
- POSTED
- time Frame
- Day 100 after transplant.
- title
- Actuarial Probability of Donor Hematopoietic Engraftment (Defined as at Least 50% Donor DNA in Bone Marrow at Day 100).
- type
- PRIMARY
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice